Prostate cancer is the third common cause of death in men over the age of 75. Prostate cancer displays a range of clinical behaviour, from slow growing tumor of no clinical significance to an aggressively metastatic and fatal disease. Prostate cancer rarely causes any symptoms until it is advanced or metastasized, after which chances of survival become minimal. Hence, biomarkers that can diagnose prostate cancer at a very early stage are required which may also help in accurately determining the tumor grade and the effective treatment needed.
We collect urine from three different categories of patients, that is, Prostatitis, Benign Prostate Hyperplasia (BPH) and Prostate Cancer and prepare it for proteomics study using the mass spectrometer.
Under disease conditions, certain proteins are expressed differentially either by up-regulation (increased levels) or down-regulation (decreased levels) of their genes. Thus, we hypothesize that the comparison of the urine proteome profiles of normal individuals with that of patients suffering from prostate cancer may help in identifying a suitable diagnostic biomarker.